

# TAKEDA ONCOLOGY IS COMMITTED TO THE ADVANCEMENT OF INNOVATIVE THERAPIES: ONCOLOGY DEVELOPMENT PIPELINE

PROGRAM	DESCRIPTION	DISEASE(S) UNDER INVESTIGATION	PHASE 1	PHASE 2	PHASE 3
<b>BRENTUXIMAB VEDOTIN<sup>1</sup></b>	CD30 Antibody Drug Conjugate	Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma			
<b>BRIGATINIB</b>	ALK Inhibitor	Non-small Cell Lung Cancer			
<b>IXAZOMIB</b>	Proteasome Inhibitor	Multiple Myeloma, Amyloidosis			
<b>PEVONEDISTAT</b>	Nedd8-Activating Enzyme Inhibitor	High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia Solid Tumors			
<b>PONATINIB<sup>2</sup></b>	BCR-ABL Inhibitor	Chronic Myeloid Leukemia Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia			
<b>SAPANISERTIB (TAK-228)</b>	TORC1/TORC2 Inhibitor	Endometrial Cancer Solid Tumors			
<b>TAK-659</b>	SYK/FLT-3 Inhibitor	Lymphoma, Acute Myelogenous Leukemia Solid Tumors			
<b>TAK-931</b>	CDC7 Inhibitor	Pancreatic Cancer, Colorectal Cancer Solid Tumors			
<b>CABOZANTINIB<sup>3</sup></b>	MET, VEGF, AXL and RET Inhibitor	Renal Cell Carcinoma			
<b>VEDOLIZUMAB</b>	Anti- $\alpha$ 4 $\beta$ 7 Antibody	Graft versus Host Disease			
<b>NIRAPARIB<sup>4</sup></b>	PARP Inhibitor	Ovarian Cancer			
<b>TAK-522 (XMT-1522)<sup>5</sup></b>	HER2 Dolaflexin Antibody Drug Conjugate	Breast Cancer			
<b>TAK-788 (AP32788)</b>	EGFR/HER2 Inhibitor	Non-small Cell Lung Cancer			
<b>TAK-573</b>	CD38-targeted IgG4 fused with attenuated IFN $\alpha$	Multiple Myeloma			
<b>TAK-164</b>	Anti-guanylyl cyclase C antibody drug conjugate	Pancreatic Cancer, Colorectal Cancer			

All programs have Global Development Rights unless otherwise noted.

<sup>1</sup> Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. <sup>2</sup> Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories). <sup>3</sup> Japan Only. <sup>4</sup> Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. <sup>5</sup> Ex-US, Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc.